门诊环境下流感疫苗中等有效性:中国北京2023/24季节检测阴性设计研究
该研究基于北京2023年10月至2024年3月流感病毒学监测,纳入18665例流感样病例,采用检测阴性设计评估门诊就诊实验室确诊流感的疫苗有效性。6362例(34.1%)流感阳性,主要流行株为A(H3N2)和B(Victoria),总疫苗接种率8.7%,调整后总疫苗有效性为44.8%,对B(Victoria)最高为52.2%。
要点
- 2023/24季节北京门诊流感疫苗总有效性为44.8%,属中等水平。
- 对B(Victoria)有效性最高为52.2%,其次为A(H3N2)和A(H1N1)pdm09。
- 19-59岁年龄组有效性最高为72.4%,当季仅接种者有效性为48.3%。
核心结论
- 研究表明流感疫苗具有中等有效性,对B(Victoria)有效性最佳,其次为A(H3N2)和A(H1N1)pdm09。
- 流感疫苗有效性在学龄儿童和老年人中相对较高。
- 未来需要一致的长期研究来评估流感疫苗的保护效果。
研究设计与样本
- 基于监测的研究纳入2023年10月至2024年3月北京所有接受流感病毒学监测的拭子患者。
- 采用检测阴性设计评估门诊就诊实验室确诊流感的疫苗有效性,并计算流感疫苗接种率。
- 病例为流感检测阳性的流感样病例患者,对照为流感阴性的流感样病例患者。
- 共纳入18665例流感样病例患者并采集拭子。
主要发现
- 6362例(34.1%)流感检测阳性,主要流行株为A(H3N2)和B(Victoria)。
- 总流感疫苗接种率为8.7%,按性别、年龄、地区、慢性病和发病月份差异有统计学意义(P<0.05)。
- 调整后对所有流感疫苗有效性为中等水平44.8%,对B(Victoria)最高为52.2%,19-59岁年龄组最高为72.4%,当季仅接种者最高为48.3%。
关键数值与推荐
- 调整后对所有流感疫苗有效性为44.8%。
- 对B(Victoria)疫苗有效性最高为52.2%。
- 19-59岁年龄组疫苗有效性最高为72.4%。
- 当季仅接种者疫苗有效性最高为48.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来需要一致的长期研究来评估流感疫苗的保护效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The objective of our study was to estimate the influenza vaccine effectiveness for 2023/24 epidemic of co-circulating influenza A(H3N2) and B(Victoria) viruses in Beijing, China. METHODS: The surveillance-based study included all swabbed patients through influenza virological surveillance in Beijing, between October 2023 and March 2024. A Test-Negative Design(TND) was used to estimate influenza vaccine effectiveness(VE) against medically- attended laboratory-confirmed influenza in outpatient settings, also calculated the influenza vaccination rate(IVR). Cases were influenza-like illness (ILI) patients who tested positive for influenza, and controls were ILI who influenza negative patients. RESULTS: A total of 18,665 ILI patients were enrolled and swabbed. Among them, 6362(34.1 %) tested positive for influenza, major epidemic strain was A(H3N2) and B(Victoria). The overall IVR was 8.7 %, and the differences of IVR by gender, age, region, chronic conditions and month of onset were statistically significant(P<0.05). The adjusted VE against all influenza was moderate at 44.8 %, with the highest for B (Victoria) at 52.2 %, the highest for 19-59 age at 72.4 %, and the highest when vaccinated only in current season at 48.3 %. CONCLUSION: Our study suggested the influenza vaccine has moderate effectiveness, with the best VE against B(Victoria), followed by A(H3N2) and A(H1N1)pdm09 in Beijing, 2023/24 season. Meanwhile, the influenza VE was relatively high in school-age children and the elderly. Consistent long-term studies are required in the future to evaluate the protect effect of influenza vaccine.
引用
- Zhang J, Zhang L, Li J, et al. Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season. Vaccine. 2024. PMID: 39731809. doi:10.1016/j.vaccine.2024.126662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。